FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3135619720> ?p ?o ?g. }

• W3135619720 endingPage "477.e7" @default.
• W3135619720 startingPage "477.e1" @default.
• W3135619720 abstract "Preemptive administration of tocilizumab (toci) to manage cytokine release syndrome (CRS) after chimeric antigen receptor T cell (CAR-T) therapy may reduce rates of serious CRS but conversely may worsen neurotoxicity or risk of infections. Optimal toci administration strategies for patients with relapsed/refractory multiple myeloma (RRMM) receiving B cell maturation antigen (BCMA)-directed CAR-T therapies have not been evaluated. The objective of this study was to identify whether shorter time-to-toci intervals (hours between first fever attributed to CRS and first dose of toci) have any impact on therapy-related toxicities or clinical outcomes among patients with RRMM receiving BCMA-directed CAR-T therapies. We retrospectively analyzed our institution's experience with 4 BCMA-directed CAR-T therapies (idecabtagene vicleucel, bb21217, ciltacabtagene autoleucel, and orvacabtagene autoceucel) for RRMM over a 3-year period ending in June 2020. We divided patients based on the administration of toci and median time-to-toci interval into early-toci (time-to-toci ≤50th percentile), late-toci (time-to-toci >50th percentile), and no-toci (no toci received) groups. We compared the early-toci and late-toci groups with regard to patient characteristics, weight-based CAR-T toxicities, selected toxicities (CRS, neurotoxicity, macrophage activation syndrome, or infections), and clinical outcomes. Of 50 analyzed patients with a median follow-up of 15.3 months, 76% (n = 38) received ≥1 dose of toci (range, 1 to 3) and were classified into early-toci (time-to-toci ≤12 hours) or late-toci (time-to-toci >12 hours) groups. The 2 groups (n = 19 each) had similar CRS grade distributions, hours to CRS onset, CRS-related biomarkers, and incidences of neurotoxicity or severe infections; however, weight-adjusted CAR-T cell doses were higher in the early-toci group (median 5.99 versus 3.80 × 106 cells/kg, P < 0.01). Peak CRS grades (range, 0 to 2) using American Society for Transplantation and Cellular Therapy consensus criteria, neurotoxicity rates, and rates of severe infections were similar between groups; however, the median CRS duration was 18.6 hours for the early-toci group versus 84.7 hours for the late-toci group. The median progression-free survival was 35.7 months in the early-toci group and 13.2 months in the late-toci group. While limited by small sample size and known confounders such as CAR-T cell dose, our analysis suggests that preemptive toci strategies for CRS management with BCMA-directed CAR-T therapy—specifically, toci administration within 12 hours of the first fever attributed to CRS—do not appear to increase rates of therapy-related toxicities or compromise efficacy. However, total CRS duration may be shorter with early-toci workflows. Prospective validation of our findings may lead to improved safety and cost-effectiveness profiles for CAR-T therapy in RRMM." @default.
• W3135619720 created "2021-03-15" @default.
• W3135619720 creator A5011954777 @default.
• W3135619720 creator A5012169173 @default.
• W3135619720 creator A5022331310 @default.
• W3135619720 creator A5022413830 @default.
• W3135619720 creator A5049480713 @default.
• W3135619720 creator A5053904944 @default.
• W3135619720 creator A5074319772 @default.
• W3135619720 creator A5077169512 @default.
• W3135619720 creator A5083444057 @default.
• W3135619720 creator A5083698821 @default.
• W3135619720 creator A5090273676 @default.
• W3135619720 date "2021-06-01" @default.
• W3135619720 modified "2023-10-11" @default.
• W3135619720 title "Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma" @default.
• W3135619720 cites W2082708772 @default.
• W3135619720 cites W2128192762 @default.
• W3135619720 cites W2486629951 @default.
• W3135619720 cites W2766745670 @default.
• W3135619720 cites W2796022095 @default.
• W3135619720 cites W2892450953 @default.
• W3135619720 cites W2901262057 @default.
• W3135619720 cites W2905654445 @default.
• W3135619720 cites W2906344733 @default.
• W3135619720 cites W2916606137 @default.
• W3135619720 cites W2933778904 @default.
• W3135619720 cites W2942621614 @default.
• W3135619720 cites W2946644350 @default.
• W3135619720 cites W2980542859 @default.
• W3135619720 cites W2982142006 @default.
• W3135619720 cites W2990005952 @default.
• W3135619720 cites W3001939352 @default.
• W3135619720 cites W3006655689 @default.
• W3135619720 cites W3011906108 @default.
• W3135619720 cites W3028760088 @default.
• W3135619720 cites W3031492407 @default.
• W3135619720 cites W3033952266 @default.
• W3135619720 cites W3037830886 @default.
• W3135619720 cites W3046016469 @default.
• W3135619720 cites W3046823850 @default.
• W3135619720 cites W3048777956 @default.
• W3135619720 cites W3082442530 @default.
• W3135619720 cites W3087079268 @default.
• W3135619720 cites W3092235509 @default.
• W3135619720 cites W3094874745 @default.
• W3135619720 cites W3094888741 @default.
• W3135619720 cites W3096689722 @default.
• W3135619720 cites W3097343073 @default.
• W3135619720 cites W3097902874 @default.
• W3135619720 cites W3097912792 @default.
• W3135619720 cites W3106794880 @default.
• W3135619720 cites W3119718700 @default.
• W3135619720 cites W4237550642 @default.
• W3135619720 doi "https://doi.org/10.1016/j.jtct.2021.03.004" @default.
• W3135619720 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33831353" @default.
• W3135619720 hasPublicationYear "2021" @default.
• W3135619720 type Work @default.
• W3135619720 sameAs 3135619720 @default.
• W3135619720 citedByCount "12" @default.
• W3135619720 countsByYear W31356197202021 @default.
• W3135619720 countsByYear W31356197202022 @default.
• W3135619720 countsByYear W31356197202023 @default.
• W3135619720 crossrefType "journal-article" @default.
• W3135619720 hasAuthorship W3135619720A5011954777 @default.
• W3135619720 hasAuthorship W3135619720A5012169173 @default.
• W3135619720 hasAuthorship W3135619720A5022331310 @default.
• W3135619720 hasAuthorship W3135619720A5022413830 @default.
• W3135619720 hasAuthorship W3135619720A5049480713 @default.
• W3135619720 hasAuthorship W3135619720A5053904944 @default.
• W3135619720 hasAuthorship W3135619720A5074319772 @default.
• W3135619720 hasAuthorship W3135619720A5077169512 @default.
• W3135619720 hasAuthorship W3135619720A5083444057 @default.
• W3135619720 hasAuthorship W3135619720A5083698821 @default.
• W3135619720 hasAuthorship W3135619720A5090273676 @default.
• W3135619720 hasBestOaLocation W31356197201 @default.
• W3135619720 hasConcept C126322002 @default.
• W3135619720 hasConcept C147483822 @default.
• W3135619720 hasConcept C203014093 @default.
• W3135619720 hasConcept C2776090121 @default.
• W3135619720 hasConcept C2776364478 @default.
• W3135619720 hasConcept C2777178219 @default.
• W3135619720 hasConcept C2777575956 @default.
• W3135619720 hasConcept C2780850621 @default.
• W3135619720 hasConcept C3875195 @default.
• W3135619720 hasConcept C71924100 @default.
• W3135619720 hasConcept C8891405 @default.
• W3135619720 hasConcept C90924648 @default.
• W3135619720 hasConceptScore W3135619720C126322002 @default.
• W3135619720 hasConceptScore W3135619720C147483822 @default.
• W3135619720 hasConceptScore W3135619720C203014093 @default.
• W3135619720 hasConceptScore W3135619720C2776090121 @default.
• W3135619720 hasConceptScore W3135619720C2776364478 @default.
• W3135619720 hasConceptScore W3135619720C2777178219 @default.
• W3135619720 hasConceptScore W3135619720C2777575956 @default.
• W3135619720 hasConceptScore W3135619720C2780850621 @default.
• W3135619720 hasConceptScore W3135619720C3875195 @default.
• W3135619720 hasConceptScore W3135619720C71924100 @default.

• next